What actually sets an early-stage price
A pre-revenue company has no earnings to multiply, no history to extrapolate and no published peer prices to copy. Every serious valuation (verdsettelse) method needs one of those three, so at pre-seed and seed (såkorn) none of them produces a defensible number on its own.
Discounted cash flow has nothing to bite on: the forecast is what is in dispute, and small changes to the growth or discount rate move the answer by multiples. What sets the price is a shorter list, and competition is the item you can do most about.
- Stage and evidence. What has been proved, meaning a working product, paying customers, and a team that can carry the company to the next investor. Designs and pilots do not count.
- Competition for the round. Three interested investors price a round differently from one. It is the largest single factor and the least discussed.
- How much you need. A round of a given size and a percentage the investors consider normal together imply a valuation, and the arithmetic often runs in that direction.
- The return the money must be able to earn. Angel portfolios are carried by a few companies, so every entry needs a plausible route to a high multiple.
The stage ladder investors carry in their heads
Most angel rounds are priced by stage and comparison. The ladder is a heuristic written in dollars, dating from 2018 and accurate to an order of magnitude. Place yourself on it before the investor does; the argument is then about where on the rung you sit.
| Stage | Where the ladder puts it |
|---|---|
| Idea and team, no product yet | Roughly NOK 2,5 to 5 million (USD 250,000–500,000), pre-money |
| Working prototype with users | A step up; 5 – 20 MNOK; the size of the step is argued, not published |
| Real paying customers | Typically 20-50 MNOK; where most Norwegian angel rounds are priced |
| Revenue growth, path to profitability | 50 MNOK and above (USD 5 million and above) |
When it comes to round sizes EBAN’s Statistics Compendium puts the average European angel investment per company at EUR 204,900 in 2024, and Norway’s visible market at EUR 25.23 million across 90 rounds, roughly EUR 280,000 each.
The multiple check: working backwards from an exit
The test that disciplines an early-stage price starts at the end. Run it on your own number before the investor does:
- Take a round of NOK 10 million at NOK 20 million pre-money. Post-money is NOK 30 million, and the investors hold 10 of 30, or 33.3 per cent.
- Say the addressable market is NOK 1.5 billion and the company can plausibly take a fifth of it, NOK 300 million of revenue. At twice sales, that is an exit at NOK 600 million, twenty times the post-money valuation.
- The investor receives less. Two further rounds at the ordinary rate of dilution (utvanning), around 20 per cent a round and rarely more than 25, roughly halve an early stake, so 33.3 per cent becomes about 16.7.
- That holding is worth some NOK 100 million at exit against NOK 10 million invested: ten times, over however many years the exit takes.
The chain explains why the number offered is lower than yours, and it narrows the dispute to three things you can bring evidence to: the market, the share you can take, or the multiple a buyer would pay.
Why a high valuation can hurt you
Every NOK of valuation is a promise of value growth, and the promise comes due at the next round. Price the same round at NOK 40 million pre-money, twice the 20, and the investors take 20 per cent for their NOK 10 million, against 33.3 before.
Halve that through later rounds and they hold about 10 per cent at exit. For the round to have returned the same ten times, the company must now exit at NOK 1 billion, against 600 million, with nothing about the business changed except the bar.
If the next round cannot clear today’s price, the company raises at a lower one, and that costs more than the arithmetic suggests. Anti-dilution clauses give this round’s investors extra shares at the lower price, so the founders pay for it; the team’s equity is reset with it, and the market reads that the plan did not hold.
Some examples: Klarna’s valuation fell 85 per cent, from USD 45.6 billion in June 2021 to USD 6.7 billion in its July 2022 raise.
Oda raised USD 151 million in December 2022 at about USD 353 million, down 61 per cent from roughly USD 900 million in April 2021, and cut 150 staff in the reset that followed.
Plan for a flat next round. A price with headroom survives a delayed sales cycle; a price with none turns an ordinary delay into a recapitalisation.
Valuation methods you will hear named
Methods come in families. Knowing the family tells you what you are being asked for, and which can be run on a company with no revenue.
- Cost. What has been spent, or what a rebuild would cost. A floor at best, since a company worth its own costs is not an investment case.
- Income. Discounted cash flow and its relatives (scenario-weighted and First Chicago variants, and the venture capital method used above). Where the dominant risk is survival, the value is discounted for the probability of failure, as Damodaran sets out for young companies.
- Market. Multiples from comparable transactions. There is no revenue to multiply here, and private early-stage prices in Norway stay between the parties, so comparisons rest on what the people in the room have seen.
- Factor. Scored frameworks: Berkus scores five elements with a ceiling on each; Risk Factor Summation, from Ohio TechAngels, scores twelve risks; the Payne scorecard weights team, market, product and competition. Each scores against a regional average pre-money, which Norway does not publish, so they work as checklists.
- Stage. The ladder above, to an order of magnitude only.
If an investor names a method, ask what inputs they are using. The argument is always about the inputs.
Arriving at your number
Build a range from the stage you can evidence, the round you need and the exit case you can defend. Then do the ownership arithmetic.
New capital divided by post-money is the share you sell. A NOK 6 million round at NOK 24 million pre-money sells 20 per cent; the same round at NOK 14 million sells 30. Decide which you can live with, knowing you will raise again and be diluted again.
The subscription price (emisjonskurs, tegningskurs in the statute) is the pre-money figure divided by the shares already issued, and the general meeting resolution must state it when the capital increase is resolved (aksjeloven § 10-1). Anything else agreed in the round that creates shares moves that price, so model it before agreeing the headline number.
Judge an offer by the percentage it costs, the milestones the money funds before the next raise, and whether the price leaves the next investor a round worth doing. A number that fails the third test is not a win, whatever the term sheet says.
Setting the number, by situation
The tests are the same for every round. What you can argue from, and who sets the number, changes with where you are.
- First raise. You are on the bottom rungs, and the evidence you can bring is the team, the prototype and any customer who has paid. Start from the round size the next milestone needs and the percentage you will sell, and let the valuation fall out of those two.
- Second raise. The last round’s price is the floor investors will test, and the milestones you promised then are the evidence for the rung you claim now. If the last price was high, check that this round clears it with headroom before asking for more.
- With a lead already committed. The lead sets the price and the others follow, so the argument is with one investor and it is about inputs. Ask which exit multiple they need and which dilution they assume, run the chain above with their numbers, and argue the market or the share you can take.
- Without a lead. Competition sets the price, so get more than one investor interested before you name a number. A number named to one investor is a ceiling that gets negotiated down; the same number named to three is a starting point.